(GH) Guardant Health - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US40131M1099
GH: Blood, Tissue, Genetic, Biopsy, Tests, Cancer, Software
Guardant Health, Inc. (NASDAQ:GH) is a leader in precision oncology, specializing in innovative blood and tissue-based tests and datasets for cancer treatment and research. The companys portfolio includes Guardant360, a comprehensive genetic testing panel, and Guardant360 LDT, which analyzes over 730 genes and supports all guideline-recommended biomarkers. Other key offerings include Guardant360 CDx, a liquid biopsy test; Guardant360 Response, a blood-only liquid biopsy; Guardant360 TissueNext, an AI-enhanced tissue-based test; and GuardantINFINITY, which provides molecular insights for cancer research and therapy development. Additionally, GuardantConnect is a software-based solution connecting patients with actionable test results to relevant clinical studies. The company also offers GuardantOMNI for advanced-stage cancer and GuardantINFORM, an in-silico platform for studying tumor evolution and treatment resistance.
Guardant Health provides a range of development services, including companion diagnostic development, clinical study setup, and regulatory support. It also offers the Shield Test for screening, Guardant Reveal for monitoring early-stage cancer patients, and the Smart Liquid Biopsy Platform. Founded in 2011 and headquartered in Palo Alto, California, the company has established itself as a pioneer in liquid biopsy technology and precision oncology solutions.
Based on the provided technical and fundamental data, here is a 3-month forecast for Guardant Health (NASDAQ:GH): - Technical Outlook: The stock is currently trading at $48.30, with a 20-day SMA of $43.63 and a 50-day SMA of $43.67, indicating short-term bullish momentum. The 200-day SMA of $34.09 suggests long-term upside potential. ATR of 2.94 signals moderate volatility. - Fundamental Outlook: With a market cap of $5.4 billion and a P/S ratio of 7.31, the company is valued at a premium, reflecting its growth prospects. The P/B ratio of 55.67 and RoE of 312.48 highlight strong equity returns. However, the absence of P/E ratios and high valuation multiples warrant caution. - 3-Month Forecast: Expect continued upward momentum in the short term, driven by strong technical indicators. Longer-term trends will depend on the companys ability to maintain growth and justify its premium valuation. Volatility is expected to remain manageable, with support from the 50-day SMA.
Additional Sources for GH Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
GH Stock Overview
Market Cap in USD | 5,406m |
Sector | Healthcare |
Industry | Diagnostics & Research |
GiC Sub-Industry | Health Care Services |
IPO / Inception | 2018-10-04 |
GH Stock Ratings
Growth Rating | -23.4 |
Fundamental | -11.7 |
Dividend Rating | 0.0 |
Rel. Strength | 170 |
Analysts | 4.59/5 |
Fair Price Momentum | 44.57 USD |
Fair Price DCF | - |
GH Dividends
No Dividends PaidGH Growth Ratios
Growth Correlation 3m | -13.8% |
Growth Correlation 12m | 73.6% |
Growth Correlation 5y | -79.9% |
CAGR 5y | -7.59% |
CAGR/Max DD 5y | -0.08 |
Sharpe Ratio 12m | -0.06 |
Alpha | 158.50 |
Beta | 1.636 |
Volatility | 66.63% |
Current Volume | 2451.6k |
Average Volume 20d | 1867.6k |
As of April 30, 2025, the stock is trading at USD 49.53 with a total of 2,451,587 shares traded.
Over the past week, the price has changed by +13.08%, over one month by +16.27%, over three months by +3.95% and over the past year by +172.29%.
Neither. Based on ValueRay Fundamental Analyses, Guardant Health is currently (April 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -11.68 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of GH as of April 2025 is 44.57. This means that GH is currently overvalued and has a potential downside of -10.01%.
Guardant Health has received a consensus analysts rating of 4.59. Therefor, it is recommend to buy GH.
- Strong Buy: 14
- Buy: 7
- Hold: 1
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, GH Guardant Health will be worth about 50.8 in April 2026. The stock is currently trading at 49.53. This means that the stock has a potential upside of +2.52%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 56.2 | 13.5% |
Analysts Target Price | 44.1 | -11% |
ValueRay Target Price | 50.8 | 2.5% |